Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q1 2024 call → NOWe need to determine if management's forward account is based on narrating what its counterparties are doing and scaling. The question asks: does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? That is, does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to look at the transcript. Management discusses several things: VAC approvals, burn admissions, RECELL GO launch, PermeaDerm, international expansion, vitiligo, etc. The question is whether they are narrating counterparties' own trajectories. For example, they talk about VAC committees approving accounts. That is about hospitals approving the product for use. But is that a counterparty trajectory? The hospitals are customers, but the narrative is about the company's sales process to get approvals. They mention "we expect 46 accounts to be approved" - that is about the company's pipeline of accounts, not about the counterparties' own expansion. They talk about burn admissions being down, but that's a market condition. They talk about RECELL GO being easier to use, which is a product improvement. They talk about international distributors, but those are prospects they hope to sign. They talk about vitiligo study, but that's their own study. The key is: does management describe what specific customers or partners are themselves doing to scale up? For example, are they saying "our lead customer is opening new sites" or "our distributor is expanding into new regions"? I don't see that. They mention "our top 28 burn accounts will be prioritized for conversion to RECELL GO" - that is about the company's own prioritization, not about those accounts' own growth. They mention "we have had a total of 178 submissions to VACs" - that's about the company's sales process. They mention "we expect 46 accounts to be approved" - again, that's about the company's pipeline.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.